HCM
HUTCHMED DRC
NASDAQ: HCM · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$12.87
-2.69% today
Updated 2026-06-05
Market cap
$1.96B
P/E ratio
4.29
P/S ratio
3.56x
EPS (TTM)
$2.65
Dividend yield
—
52W range
$11 – $20
Volume
0.0M
WallStSmart proprietary scores
43
out of 100
Grade: D
Sell
Investment rating
3.3
Growth
D8.0
Quality
A6.0
Profitability
B8.3
Valuation
A3/9
Piotroski F-Score
Weak
2.3
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$22.85
+77.54%
12-Month target
$13.80
+7.23%
Intrinsic (DCF)
$26.99
Margin of safety
+44.02%
2 Strong Buy9 Buy2 Hold1 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 83.30% — above average
+ ROE 37.71% — strong efficiency
+ 44.02% below intrinsic value
+ Debt/equity 0.08x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Negative free cash flow $-79.01M
- Revenue declining -16.50% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $426.41M | $838.00M | $630.20M | $549.96M | $548.51M |
| Net income | $-360.83M | $100.78M | $37.73M | $458.12M | $458.12M |
| EPS | — | — | — | — | $2.65 |
| Free cash flow | $-305.26M | $186.65M | $-17.44M | $-79.01M | $-79.01M |
| Profit margin | -84.62% | 12.03% | 5.99% | 83.30% | 83.30% |
Peer comparison
Smart narrative
HUTCHMED DRC trades at $12.87. representing a P/E of 4.29x trailing earnings. Our Smart Value Score of 43/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 2.26, it sits in the grey zone. TTM revenue stands at $548.51M. with profit margins at 83.30%. Our DCF model estimates intrinsic value at $26.99.
Frequently asked questions
What is HUTCHMED DRC's stock price?
HUTCHMED DRC (HCM) trades at $12.87, on a P/E of 4.3x and a P/S of 3.6x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is HUTCHMED DRC overvalued?
HUTCHMED DRC carries a Smart Value Score of 43/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $26.99 versus the $12.87 price, a 44.0% margin of safety on a cash flow basis.
What is the price target of HUTCHMED DRC (HCM)?
The 12-month analyst consensus target is $22.85, about 77.5% above the current $12.87. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of HUTCHMED DRC (HCM)?
Our DCF model estimates intrinsic value at $26.99, a +44.0% margin of safety versus today's $12.87. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is HUTCHMED DRC's revenue?
HUTCHMED DRC's trailing twelve-month revenue is $548.51M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
HUTCHMED DRC's Altman Z-Score is 2.26, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio3.56x
ROE37.71%
Beta0.38
50D MA$13.85
200D MA$14.71
Shares out0.17B
Float0.51B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—